Cambria 1 for ER+/HER2- Early Stage Breast Cancer after Surgery - Clinical Trial
What is the Purpose of this Study?
We are doing this study to determine if long-term treatment with camizestrant after surgery is a safe and effective option for treating patients with early-stage ER+/HER2- breast cancer. We want to compare the outcomes of using camizestrant to current standard of care treatments (endocrine therapy).
Early Stage ER+/HER2- Breast Cancer
Who Can Participate in the Study?
Adults ages 18+ who:
- Are diagnosed with intermediate or high-risk early stage ER+/HER2- breast cancer
- Have had surgery to remove breast cancer tissue
- Have been taking endocrine therapy for 2-5 years after surgery
For more information about who can join this study, please contact the study team at caroline.morales@duke.edu.
What is Involved?
If you choose to join this study, you will:
- Get a random assignment (like a coin flip) to 1 of 2 groups
-- One group will take physician’s choice endocrine therapy daily
-- The other group will take camizestrant daily
- Answer questionnaires
- Have blood draws
- Have imaging scans
- Have eye exams
- Have heart scans (EKGs)
- Give us permission to use your stored tissue samples
After study treatment, you will continue to return to our clinic for follow-up visits to see how you are doing.
Study Details
